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S U M M A R Y
Background: Hematological abnormalities are common manifestations of advanced HIV-1 infection that
could affect the outcomes of highly-active antiretroviral therapy (HAART). Althoughmost HIV-1-infected
individuals live in resource-constrained countries, there is little information about the frequency of
hematological abnormalities such as anemia, neutropenia, and thrombocytopenia among individuals
with advanced HIV-1 disease.
Methods: This study compared the prevalence of pre-antiretroviral therapy hematological abnormalities
among 1571 participants in a randomized trial of antiretroviral efﬁcacy in Africa, Asia, South America, the
Caribbean,and theUSA.Potential covariates foranemia,neutropenia, and thrombocytopeniawere identiﬁed
in univariate analyses and evaluated in separate multivariable models for each hematological condition.
Results: The frequencies of neutropenia (absolute neutrophil count 1.3  109/l), anemia (hemoglobin
10 g/dl), and thrombocytopenia (platelets 125  109/l) at initiation of antiretroviral therapy were
14%, 12%, and 7%, respectively, and varied by country (p < 0.0001 for each). In multivariable models,
anemia was associated with gender, platelet count, and country; neutropenia was associated with CD4+
lymphocyte and platelet counts; and thrombocytopenia was associated with country, gender, and
chronic hepatitis B infection.
Conclusions: Differences in the frequency of pretreatment hematological abnormalities could have
important implications for the choice of antiretroviral regimen in resource-constrained settings.
 2010 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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journa l homepage: www.e lsev ier .com/ locate / i j idHematological abnormalities (neutropenia, anemia, and throm-
bocytopenia) are common manifestations of advanced HIV-1
infection that could potentially limit the use of some components
of antiretroviral therapy (ART) regimens.1,2 It is not known if the
prevalence of hematological abnormalities at the time of ART
initiation in persons with advanced HIV-1 infection differs around
the world. Knowledge of how pretreatment hematological
parameters compare across diverse settings is needed to inform
recommendations for the choice of initial antiretroviral regimens* Corresponding author. Tel.: +27 11 276 8800; fax: +27 11 482 2130.
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doi:10.1016/j.ijid.2010.08.002in developing countries. The present study estimated the preva-
lence of neutropenia, anemia, and thrombocytopenia at the
initiation of ART, and investigated associations between each of
pretreatment neutropenia, anemia, and thrombocytopenia and
baseline covariates of race, geographic location, gender, HIV-1
disease status, and nutritional status.
1. Methods
1.1. Study population
The AIDS Clinical Trials Group (ACTG) Prospective Evaluation of
Antiretrovirals in Resource-Limited Settings (PEARLS) study is anses. Published by Elsevier Ltd. All rights reserved.
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that enrolled 1571 antiretroviral-naı¨ve participants in nine
countries (Brazil, Haiti, India, Malawi, Peru, South Africa, Thailand,
the USA, and Zimbabwe) between May 2005 and August 2007.
Entry criteria included CD4+ lymphocyte count <300 cells/mm3,
ART-naı¨ve, no recent acute illness (i.e., pneumonia, gastroenteritis,
or pelvic inﬂammatory disease) or opportunistic infections (OI),
absolute neutrophil count (ANC) >0.75  109/l, hemoglobin
>7.5 g/dl, platelet count >50  109/l, calculated creatinine clear-
ance >60 ml/min, aspartate aminotransferase (AST), alanine
aminotransferase (ALT), and alkaline phosphatase less than ﬁve
times the upper limit of normal, and total bilirubin less than 2.5-
fold above the upper limit of normal. Womenwho received single-
dose nevirapine or zidovudine for any period of time during
pregnancy were included. Women with the use of two or more
antiretroviral drugs to prevent vertical transmission within 6
months of enrollment for greater than 7 days were excluded.
Patients were excluded from the study if they had chemotherapy
or radiation therapy within 45 days of enrollment. Informed
consent was obtained from all participants, and the human
experimentation guidelines of the US Department of Health and
Human Services and local site institutional review boards and
ethics committees were followed.
1.2. Data analysis
Neutropenia was deﬁned as an ANC 1.3  109/l and anemia
was deﬁned as a hemoglobin 10.0 g/dl. Anemia was further
evaluated by the mean corpuscular volume (MCV) and deﬁned as
microcytic if the MCV was <82 ﬂ, normal if between 82 and 100 ﬂ,
and macrocytic if >100 ﬂ. Thrombocytopenia was deﬁned as a
platelet count <125  109/l.
Multivariable logistic methods were used to explore the
correlates of baseline anemia, neutropenia, and thrombocytopenia
as individual outcome variables. Covariates explored included the
following: age; screening CD4+ lymphocyte count; plasma HIV-1
RNA; bodymass index (BMI); ANC (except for neutropenia); platelet
count (except for thrombocytopenia); hemoglobin level (except for
anemia); history of AIDS-related diagnoses; self-reported quality of
life category (obtained by standardized interview); Karnofsky score
group; self-identiﬁed race; self-identiﬁed ethnicity; sex; use of
alternative therapies; current ongoing AIDS diagnosis; and hepatitis
B surface antigen (HBsAg) positivity.
A purposeful variable selection method (as opposed to a
mechanical method) was used to build multivariable logistic
models for each of the three hematological outcomes of interest.
An initial multivariable model included all covariates whose
likelihood ratio p-value from the univariate model was <0.2.
More parsimonious models were explored by removal of
covariates one at a time, starting with the covariate with the
largest p-value. The Akaike’s information criterion (AIC) adjust-
ment to the log likelihood statistic (which penalizes for more
complex models), was used to compare nested models. Even if
removal of the covariate did not signiﬁcantly affect the model ﬁt
by the AIC, if it was a confounder or effect modiﬁer (e.g., resulted
in>20% change in the parameter estimate of another covariate in
the model) then the covariate was retained in the model.
Confounding between country and race was initially handled by
stratifying models by country. The resulting preliminary main
effects model was then tested to see if continuous covariates
were linear in the logit (and if not, groupings suggested by the
data were chosen for best ﬁt). Finally, each two-way interaction
between covariates was introduced into the model one at a time.
Goodness of ﬁt for the unstratiﬁed model was considered by
using the Hosmer and Lemeshow goodness-of-ﬁt test. In ﬁnal,
non-stratiﬁed models, the country effect was parameterized asdifference from overall countries (rather than using a reference
group). Estimated (adjusted) odds ratios (AOR) and correspond-
ing 95% conﬁdence intervals (CIs) for covariates in the ﬁnal
model are presented here.
2. Results
Complete baseline hematological datawere available for 1532 of
1571 participants (98%). The study population was 53% male,
median age 34 years, with a median weight of 60.3 kg and BMI of
22.3 kg/m2. Themedian CD4 lymphocyte count was 172 cells/mm3.
Anemia was present in 187 participants (11.9%; 95% CI 10.3–
13.6%). Fifty percent of anemias were microcytic and 50% were
normocytic; macrocytic anemia was uncommon (one case). The
odds of anemia were associated with having a previous AIDS-
deﬁning diagnosis (AOR 1.9; 95% CI 1.1–3.3) and BMI (AOR for each
5-unit decrease in BMI 1.5; 95% CI 1.2–1.9). Females had higher
odds of anemia than males, but the magnitude of the odds ratio
depended on CD4+ cell count: 50 cells/mm3 (AOR 3.0; 95% CI 1.8–
5.0); 150 cells/mm3 (AOR 5.0; 95% CI 3.2–7.8); 250 cells/mm3 (AOR
8.3; 95% CI 3.8–18.2). Anemia prevalence varied by country
(Figure 1A; p < 0.0001) and the prevalence of anemia was highest
in Malawi, Haiti, South Africa, and Zimbabwe. Signiﬁcant
heterogeneity in odds of anemia by country remained after
controlling for BMI, gender, platelet count, history of AIDS OI, and
screening CD4+ cell count (p = 0.009); odds for anemia were
highest in South Africa (AOR 1.8; 95% CI 1.2–2.7), Haiti (AOR 1.6;
95% CI 0.9–2.7), and Malawi (AOR 1.5; 95% CI 1.1–2.2). Only 36
women took zidovudine for preventing mother-to-child transmis-
sion for an average of 50.9 days at different times of exposure prior
to enrollment in the study.
Neutropenia was present in 224 participants (14.3%; 95% CI
12.6–16.1%). The odds of neutropenia were 0.85 (95% CI 0.77–0.94)
for every 50 cells/mm3 increase in CD4 lymphocytes; 0.6 (95% CI
0.5–0.7) for every 100  109/l increase in platelets; and 0.7 (95% CI
0.4–1.1) for every increase of hemoglobin by 5 mg/dl. Compared to
men, women had a higher odds of neutropenia (AOR 1.3; 95% CI
0.9–1.9), and compared to Hispanics, non-Hispanics had higher
odds (AOR 1.5; 95% CI 0.7–3.4), whereas other ethnicities (small
groups) had lower odds (AOR 0.4; 95% CI 0.2–0.8). The prevalence
of neutropenia was associated with country (Figure 1B;
p < 0.0001): neutropenia was highest in Malawi, Zimbabwe, Haiti,
the USA, and South Africa. Signiﬁcant heterogeneity in odds of
neutropenia by country remained after controlling for CD4+
lymphocyte count, hemoglobin, platelets, sex, and ethnicity
(p < 0.0001). The adjusted odds of neutropenia were greatest in
Malawi (AOR 2.3; 95% CI 1.5–3.3), Haiti (AOR 2.2; 95% CI 1.3–3.6),
and Zimbabwe (AOR 1.6; 95% CI 1.0–2.6).
Thrombocytopenia was present in 113 participants (7.2%; 95%
CI 6–8.6%). Thrombocytopenia was associated with HBsAg (AOR
2.3; 95% CI 1.1–4.3) and decreased odds were associated with
female sex (AOR 0.5; 95% CI 0.3–0.8) and ANC <1.75  109/l (AOR
4.3; 95% CI 2.0–10.7). Thrombocytopenia was associated with
country (Figure 1C; p < 0.0001) with highest prevalences in India,
Brazil, Malawi, and the USA. After controlling for HBsAg, sex, and
ANC, signiﬁcant heterogeneity remained across countries
(p < 0.0001). The adjusted odds of thrombocytopenia were great-
est in India (AOR 3.7; 95% CI 2.3–5.8), Brazil (AOR 2.2; 95% CI 1.3–
3.6), and Malawi (AOR 1.8; 95% CI 1.1–3.0).
Out of the 1554 persons with all three measurements at
baseline (out of 1571 randomized), 18 (or 1.2%) had both
neutropenia and thrombocytopenia, 14 (or 0.9%) had both anemia
and thrombocytopenia, 34 (or 2.2%) had both anemia and
neutropenia, and ﬁve (or 0.3%) had pancytopenia. Overall then,
a total of 71 (or 4.6%) participants with all three evaluations had
























































Figure 1. Prevalence of hematological abnormalities prior to initiation of
antiretroviral therapy, by country. (A) Anemia, deﬁned as a hemoglobin 10.0 g/
dl. (B) Neutropenia, deﬁned as an absolute neutrophil count 1.3  109/l. (C)
Thrombocytopenia, deﬁned as a platelet count less than 125  109/l.
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The PEARLS study provides the ﬁrst comparative analysis of
hematological abnormalities among people with advanced untreat-
ed HIV-1 infection around the world. Our study is unique because
hematological data were collected prospectively from treatment-
naı¨ve individuals at the time of entry into a clinical trial of ART in
nine countries in diverse geographic settings. Because participants
were required tomeet uniform inclusion and exclusion criteria prior
to study entry, the study populationwasmore homogeneous across
geographic areas than independent cohorts.
Anemia is an important hematological marker because it has
been reported to be a signiﬁcant independent risk factor for
mortality in HIV-1-infected patients.3 The high rate of anemia in
Africa and Haiti could be related to the levels of poverty,
malnutrition, and the overall poor economic state in these areas
of the world. The gross domestic product (GDP) purchasing power
parity (PPP) per capita in Haiti, Malawi, and Zimbabwe are
US$1317, US$836, and US$236, respectively, compared to Thai-
land, Peru, Brazil, and the USA, where the GDP PPP are US$8239,
US$8594, US$10 466, and US$47 700, respectively.4
Fifty percent of the anemias observed at baseline were
microcytic and the majority (speciﬁcally 360 or 67% of 541) ofparticipants in Africa were women (of whom 93% reported
reproductive potential, and only 4% were older than 50 years),
therefore the signiﬁcant percentage of microcytic anemia may
presumably have been from menstrual-related blood loss and/or
recent pregnancy. We cannot exclude the possibility that human
genetics were a factor in the occurrence of anemia in this study.
However, inheritable causes of anemia, such as sickle cell trait/
disease and thalassemias, are not as prevalent in the southern
African countries where this study was performed.5,6
Other studies have provided evidence that there are high risks
of severe anemia after starting ART in resource-limited settings. In
the DART study in Zimbabwe and Uganda there was a higher
prevalence of severe anemia (hemoglobin<6.5 g/dl) in patients on
zidovudine than expected from data from developed countries.7
Predictive factors for severe anemia after starting antiretroviral
medication in DART were female sex, baseline anemia, low CD4,
and lowBMI. Our study also showed similar risk factors for anemia.
Anemia has been shown to be associated with HIV disease
progression. There are several proposed mechanisms of interrup-
tion of hematopoiesis through disruption of several cytokine
mechanisms by HIV infection of bone marrow stromal cells and
macrophages.8 Pretreatment anemia was also highly predictive of
anemia after initiation of zidovudine in the TAHOD cohort from the
Asia- Paciﬁc region, indicating that in areas of the world where
there are signiﬁcant rates of baseline anemia, hematological
parameters should be monitored closely after initiation of
zidovudine.9 Previous zidovudine usage for pregnancy may have
contributed to the baseline anemia in women, however the overall
small exposure pre-enrolment to the study makes this unlikely.
Our ﬁnding from the PEARLS study that the prevalence of
pretreatment anemia differs across diverse resource-limited
settings suggests that geographic location may be associated with
the risk of anemia after initiation of ART.
Neutropenia is a common hematological abnormality in
persons with untreated HIV-1 infection. Several mechanisms for
neutropenia in HIV-1 infection have been proposed, including
decreased production of granulocyte colony-stimulating factor (G-
CSF), a soluble inhibitory substance that decreases neutrophil
production,10–12 and autoimmunity.13 The Women’s Interagency
HIV Study cohort found baseline neutropenia in 44% of this cohort
and a longitudinal analysis found that worsening HIV-1 disease
was associated with subsequent neutropenia.1 Neutropenia was
observed in 21% of patients prior to starting co-trimoxazole
prophylaxis in Coˆte d’Ivoire.14 Our ﬁnding that neutropenia in the
PEARLS cohort was independently associated with CD4+ lympho-
cyte and platelet counts, hemoglobin level, sex, ethnicity, and
country, suggests that the stage of HIV-1 infection is an important
contributor to pre-treatment neutropenia.
Pre-antiretroviral thrombocytopenia was less commonly ob-
served than neutropenia or anemia in the PEARLS study. Interest-
ingly, the geographicdistributionof thrombocytopeniawasdifferent
than the distributions of anemia and neutropenia in PEARLS. The
highest prevalences of anemia and neutropenia were observed in
southern Africa, while the highest prevalences of thrombocytopenia
were observed in India and Brazil. Higher odds of thrombocytopenia
were independently associated with chronic active hepatitis B virus
infection (HBV, as indicated by HBsAg positivity), male gender, and
lower ANC. Thrombocytopenia in individuals with HBV can result
from increased platelet sequestration fromhypersplenism, effects of
chronic illness on platelet production and maturation, and
autoimmunity.15–17 HIV is also associated with thrombocytopenia
and may be caused by a direct effect on megakaryocytes by the HIV
virus. Anti-gp120 antibodies and platelet-speciﬁc antibodies have
also been reported on platelets in HIV-seropositive patients.13,18
While the PEARLS study provides a unique opportunity to
compare the factors associated with mild to moderate hematolog-
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important limitations. Sincepersonswithgrade3or4hematological
abnormalities19 were excluded from participation in PEARLS, it is
likely that the true prevalences of anemia, neutropenia, and
thrombocytopenia among persons initiating antiretroviral therapy
in these areas of the world are higher. The PEARLS entry criteria
likely resulted in the selection of a study group that is overall
healthier than the population of people who are initiating ART in
these areas of theworld (also known as the clinical trials or research
selection bias). Despite these limitations, the PEARLS study provides
evidence that the prevalence of hematological abnormalities in
untreatedHIV-1 infection is independently related to factors such as
geographic location, gender, and chronic co-infections. These
ﬁndings have implications for the optimal choice of initial
antiretroviral agents, monitoring of antiretroviral toxicities, and
improvement of antiretroviral treatment programs, especially in
resource-limited countries.
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